Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
Status:
Completed
Trial end date:
2012-01-06
Target enrollment:
Participant gender:
Summary
RATIONALE: Learning about the effect of exemestane and anastrozole on bone mineral density in
postmenopausal women with primary breast cancer may help plan treatment, decrease the risk of
broken bones, and help patients live more comfortably.
PURPOSE: This phase III trial is studying bone mineral density in postmenopausal women with
primary breast cancer who are receiving treatment on clinical trial CAN-NCIC-MA27.
Phase:
Phase 3
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborators:
National Cancer Institute (NCI) North Central Cancer Treatment Group Southwest Oncology Group